英语论文网

财务报告Roche Finance Report 09
Table of Contents
Roche Group 2
Finance in brief 2
Finance — 2009 in brief 3
Financial Review 4
Roche Group Consolidated Financial Statements 30
notes to the Roche Group Consolidated
Financial Statements 36
Report of Roche Management
on Internal Control over Financial Reporting 125
Report of the Statutory Auditor
on the Consolidated Financial Statements 126
Report of the Independent Auditor
on Internal Control over Financial Reporting 128
Multi-Year Overview and Supplementary Information 130
Roche Securities 136
Roche Holding Ltd, Basel 138
Financial Statements 138
Notes to the Financial Statements 140
including Board and Executive remuneration
disclosures as required by Swiss Law 142
Appropriation of Available Earnings 148
Report of the Statutory Auditor
on the Financial Statements 149
Finance — 2009 in brief Roche Finance Report 2009 3
Finance — 2009 in brief
Sales
• Group sales increased by 10% in local currencies to 49.1 billion Swiss francs. Excluding Tamiflu sales
the increase was 5% in local currencies.
• Pharmaceuticals sales increased by 11% in local currencies or 3.0 billion Swiss francs, almost twice the
global market growth thanks to virology, in particular Tamiflu, the key oncology products and Lucentis
in ophthalmology. This was achieved in spite of the reduction in CellCept sales due to the patent expiry in
the United States.
• Tamiflu sales grew sharply by 2.6 billion Swiss francs to 3.2 billion Swiss francs driven by the currentpandemic A (H1N1) 2009 influenza virus (‘swine flu’) outbreak.
• Diagnostics sales increased by 9% in local currencies to 10.1 billion Swiss francs, driven by sales growth inProfessional Diagnostics and Diabetes Care. This was more than twice the estimated IVD market growth rate.
Operating results
• Operating profit before exceptional items increased by 14% in local currencies to 15.0 billion Swiss francsthanks to strong sales growth and continuing productivity improvements, which more than covered increased
investments in research and development.
• Operating profit margin before exceptional items and at constant exchange rates increased by 1.0 percentage
points, with increases of 1.2 percentage points in the Pharmaceuticals Division and 0.4 percentage pointsin the Diagnostics Division. Exchange rates had an unfavourable impact of approximately 1 percentage point
on Group, Pharmaceuticals and Diagnostics margins.
• Research and development expenditure increased 12% in local currencies to 9.9 billion Swiss francs,representing 20.1% of Group sales, due mainly to continued investment in the strong late-stage pipeline.
• Effective 26 March 2009 Roche obtained full ownership of Genentech for a total cash consideration of 47.0 billion
US dollars or 52.7 billion Swiss francs. Exceptional restructuring costs of 2.4 billion Swiss francs wereincurred in respect of the integration of Genentech and related restructuring in the Pharmaceuticals Division,
notably of manufacturing operations.
Treasury
• As a consequence of the Genentech transaction, the Group’s treasury results changed significantly
during 2009, with the net financial result being an expense of 1.7 billion Swiss francs, primarily driven
by the higher interest expenses.
• Of the 48.2 billion Swiss francs bond and no本论文由英语论文网提供整理，提供论文代写，英语论文代写，代写论文，代写英语论文，代写留学生论文，代写英文论文，留学生论文代写相关核心关键词搜索。